Clinical Trials Privacy Policy

Safe Harbor Compliance

ImmunoGen adheres to a self-regulatory program that complies with the US-EU and the US-Swiss Safe Harbor Privacy Principles published by the US Department of Commerce, (“Safe Harbor”). For more information about the Safe Harbor program or its requirements, please refer to the US Department of Commerce website at http://www.export.gov/safeharbor/. The privacy principles in this Clinical Trials Privacy Policy are based on the Safe Harbor Privacy Principles.

Privacy Commitment

ImmunoGen is committed to its legal and ethical obligations to protect the privacy of participants in ImmunoGen-sponsored clinical trials. This policy provides general information about ImmunoGen’s clinical trial-related privacy and security practices. Clinical trial participants are encouraged to speak with their principal investigator for more specific information or to have questions answered. It is also important to read clinical trial consent forms and other study information carefully, as these documents will address matters of privacy.

ImmunoGen requires employees, partners, and clinical practitioners/sites that engage in any aspect of a clinical trial to ensure that every precaution is taken to protect the privacy, security and confidentiality of participant health information and personal data. To the greatest extent possible, ImmunoGen will not collect personal information from clinical trials. Participant identifiers (e.g. full participant name) will be removed from biological samples and written reports prior to shipment from the clinical sites and participants will be identified by assigned identifiers only.

ImmunoGen will maintain reasonable administrative, technical, and physical safeguards to prevent intentional or unintentional disclosure of health information and personal data. ImmunoGen studies are designed to collect, use, disclose, or store clinical study data for specific, legitimate and necessary purposes and to ensure that people whose data is to be collected are fully informed of the facts specific to their study. ImmunoGen will retain health information and personal data only for as long as is necessary for the purpose for which it was processed and in accordance with applicable law. ImmunoGen will only transfer personal data between countries with clear and unambiguous consent from the participant after being duly informed, unless otherwise permitted by law.

Inquiries, Complaints and Additional Information

For questions, complaints or additional information, please write to ImmunoGen at the following address:
ImmunoGen, Inc
Re: Privacy Policy Request
Executive Director, Quality
830 Winter Street,
Waltham, MA 02451

Any individual unable to resolve his or her issue directly with ImmunoGen may contact his or her local data protection authority for further assistance and information.

This Clinical Trials Privacy Policy was last updated on April 23, 2012.